Our Team

Jason joined Sanofi Ventures in 2014 with a background in early-stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at Translate Bio (fka RaNA Therapeutics), a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.

Jason’s active investments include Abcuro, AdvanCell, Atalanta Therapeutics, Character Bio, Expedition Therapeutics, Glycomine, Matchpoint Therapeutics, Nura Bio, ReCode Therapeutics, Star Therapeutics, and Vrata. Previous investments include Escient Pharmaceuticals (acquired by Incyte), Q32 Bio (NASDAQ: QTTB), Icosavax (acquired by AstraZeneca), Kymera Therapeutics (NASDAQ: KYMR), Ovid Therapeutics (NASDAQ: OVID), Science 37 (NASDAQ: SNCE), and Lysosomal Therapeutics Inc. (acquired by Bial). Jason also serves as the Chair of the Board of Trustees of the Buckingham Browne and Nichols school and the Board of Directors of The Magdalene College Foundation.

Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.

Laia joined Sanofi Ventures in 2018 with a background in early-stage biotech investing and drug development. Prior to Sanofi, Laia served as Investment Director for Ysios Capital where she led investments and served on the board of multiple early-stage companies.

Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia's active investments include Eligo Bioscience, Granite Bio, Muna Therapeutics, NodThera, OMass Therapeutics, QurAlis, SpliceBio, T-Therapeutics and Therini Bio. Previous investments and board roles include Lava Therapeutics (LVTX).

Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a Ph.D. with honors. Laia holds an M.B.A. from Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance.

Cris joined Sanofi Ventures in 2020 as a Partner to lead investments in Digital Health and Artificial Intelligence. He brings 20+ years of experience in healthtech dealmaking, company creation, scaling AI-driven emerging technologies, and creating innovation platforms for some of the world’s largest organizations.

Previously, Cris was a founding member of Johnson & Johnson Innovation, serving as Global Head of Digital Innovation where he held chief digital responsibilities across J&J’s 250 operating companies in Pharma, Consumer, and Medical Devices. Before that, he spent six years at Novartis, leading emerging technology programs within Research Informatics.

With entrepreneurial DNA, Cris is notably known for his role in the innovation economy since co-founding Ultra Light Startups, one of the largest and oldest startup venture pitch accelerators in the U.S. This platform catalyzed hundreds of companies in Boston, NYC, and Silicon Valley, leading to several acquisitions by major tech companies. Cris was named to the Boston Business Journal's 40 Under 40 list and recognized as a Top 40 Healthcare Transformer by MM&M Magazine.​

Cris is actively involved at the board level in various capacities across leading AI and digital health companies including Aetion, Carbon Health, Click Therapeutics, Empatica, Evidation, Medisafe, Nucleai, Omada Health, QuantHealth, and Trial Library. He holds a M.Sc. in Computer Information Sciences from Boston University and a B.S. in Business Administration from Suffolk University.​

Paulina joined Sanofi Ventures in 2022 with a background in early stage biotech investing and company building. Paulina’s active investments include Attovia, Avilar, Latigo, Odyssey, NextPoint, Normunity, Nuvig, Tisento, Vrata and ZagBio. Prior investments include Aliada Therapeutics (acquired by Abbvie).

Prior to joining Sanofi, Paulina was a Principal on the investment team at Omega Funds. While there Paulina incubated and served as the founding investor for Scorpion Therapeutics (acquired by Eli Lilly). Paulina’s investments also included Arrakis, IFM, Ikena (NASDAQ: IKNA), Synthekine, Theseus (NASDAQ: THRX), and Vanqua Bio.

Paulina began her career with Polaris Partners. Paulina served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Microchips Biotech (acquired by Dare Biosciences), Arsenal Medical and CAMP4 Therapeutics (NASDAQ: CAMP), where she was the Founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at MIT. During her time at MIT, Paulina founded the MIT Postdoctoral Association and served as its President. Paulina also served on the MIT Intellectual Property Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. Paulina attended East Carolina University on a full athletic scholarship and served as the captain of the women’s varsity tennis team.

Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at L.E.K. consulting where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors.

Chris currently serves on the Boards of AdvanCell Isotopes, i2O Therapeutics, Minervax, and Sudo Bio, and is a Board observer for Atalanta Therapeutics, Avilar Therapeutics, Matchpoint Therapeutics, and Nextpoint Therapeutics. He also led Sanofi Ventures’ investment in Curevo.

Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a B.S. in both Biology and Chemistry from Roger Williams University.

Meg joined Sanofi Ventures in 2021 with a background in biotech investing and business development. She previously worked as part of the External Innovation team at Vertex Pharmaceuticals and at RA Capital, a crossover investment fund.

Meg currently serves as a director for Normunity and as an observer for several companies including Draig Therapeutics, Eligo Bioscience, Korsana Biosciences, Quralis, and a stealth immunology company. Meg also supported Sanofi Ventures’ investment in Aliada Therapeutics before its acquisition by Abbvie for $1.4 billion.

Meg holds a Ph.D. in Neuroscience from Massachusetts Institute of Technology and a B.S. with Honors in Neuroscience from The Pennsylvania State University. She is also co-chair of the Board of Directors for the New England Venture Network.

Kriti joined Sanofi Ventures in 2026 with a background in healthcare services, digital health, and medtech investing. Prior to Sanofi, she spent four years at RA Capital Management on the Health Technology and Services team, investing across both public equities and venture.

Kriti holds a Ph.D. in Medical Engineering and Medical Physics from the Massachusetts Institute of Technology and a B.S. with Highest Honors in Biomedical Engineering from Harvard College.

Francesc joined Sanofi Ventures in 2024 with a background in early-stage biotech investing, technology transfer, and biotech management. Prior to his role at Sanofi, he spent three years at AdBio Partners, a pan-European venture firm specializing in early-stage therapeutic projects, where he was responsible for scouting and conducting due diligence on new investment opportunities. As one of the first hires in Barcelona, he played a key role in establishing the local office and expanding the fund's presence in the region.

Earlier in his career, Francesc served as an operational manager at Kiji Therapeutics, an emerging gene and cell therapy company, and as an innovation manager at the technology transfer office of the University of Barcelona.

Francesc holds a degree in Biochemistry from the University of Barcelona, where he also completed an MBA with a focus on biotech investments.

In addition to his professional roles, Francesc serves on the therapeutics board of YVC Collective, a network of emerging life sciences venture capital professionals.

Pierre joined Sanofi Ventures in 2024 with a background in biopharma investing. He previously worked as Analyst at Jeito Capital, where his areas of focus included oncology, cardiology, and neuroscience. Prior to Jeito Capital, Pierre worked as Researcher at Smart Immune, clinical-stage startup company developing cell therapies, as well as at Institut Imagine, leading European Center for research on genetic diseases
 
Pierre holds a Life Science Engineer’s degree from AgroParisTech, a MSc and a PhD in Biotechnology and Biotherapies from Université Paris Cité, and an MBA from the Collège des Ingénieurs. Before starting his doctoral program, Pierre was trained at Pasteur Institute and was a visiting student at the Massachusetts Institute of Technology.

Becca joined Sanofi Ventures in 2026 with a background in biopharma investing. Prior to Sanofi, she previously worked at Bain Capital Life Sciences, where she evaluated both private and public biotech companies.

Becca received her PhD in biological and biomedical sciences from Harvard University studying stem cell biology and epigenetics. She graduated with a BA in biology from Williams College.

Steve joined his current role in Sanofi Ventures in 2025 with a broad background across the pharma value chain. Steve joined Sanofi in 2020 and has been the legal partner for a variety of strategic investments, licensing, collaboration, and other related complex transactions, and has also been a key member of Sanofi product teams advancing pipeline and commercial assets.

Prior to Sanofi, Steve was in-house at Fresenius Medical Care, providing overarching strategic advice to Fresenius’ pharma and specialty pharmacy divisions.  

Steve began his legal career at Foley Hoag LLP, where he handled transaction and IP disputes for pharma and biotech companies.  

Steve earned a JD from Northwestern School of Law, cum laude and Order of the Coif, and a BA in Philosophy, summa cum laude, from the University of Illinois at Chicago. Outside of work, Steve runs an artist residency, plays in a jazz ensemble, and enjoys hiking in Vermont. 

Anne joined Sanofi Ventures in May 2023. She previously worked in various departments over the last 19 years including Digital Vaccines, business development and global digital. Anne holds a Bachelors of Science in Business Administration degree with concentration in Management. In her spare time, she enjoys the beach, walking, exploring new trails with her husband, twins and two dogs.